MAPT and frontotemporal dementia: Recent experimental evidence has related Tau-dependent FTD with dysregulation in the endocannabinoid signaling [25], which may support the pharmacological modulation of certain proteins of this system (e.g., CB2 receptors) as a promising disease-modifying therapy in this form of FTD [10, 25, 30].